Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes.

Several reports indicate that there might be differences in clinical features between Asian and Western myelodysplastic syndrome (MDS) cases. We analyzed refractory anemia (RA) in French-American-British (FAB) classification cases diagnosed in Japan and Germany to perform a more exact comparison between Asian and Western MDS types. In the first step, we analyzed agreement of morphologic diagnosis between Japanese and German hematologists. Blood and bone marrow slides of 129 patients diagnosed with FAB-RA, FAB-RA with ringed sideroblasts (RARS), or aplastic anemia were selected randomly and evaluated separately by each group. The agreements of diagnoses according to FAB and World Health Organization (WHO) classifications were 98.4% and 83.8%, respectively. Second, we compared clinical features between 131 Japanese and 597 German patients with FAB-RA. Japanese patients were significantly younger than German patients. Japanese patients had more severe cytopenias. However, prognosis of Japanese patients was significantly more favorable than that of German patients. Japanese patients had a significantly lower cumulative risk of acute leukemia evolution than did German patients. Frequency of WHO-RA in Japanese patients with FAB-RA was significantly higher than that in German patients. In conclusion, our results indicate that the clinical features of Japanese patients with FAB-RA differ from those of German patients.

[1]  K. Metze,et al.  Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. , 2004, Leukemia research.

[2]  M. Tomonaga,et al.  Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. , 2003, Leukemia research.

[3]  S. Miyawaki,et al.  Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. , 2003, Blood.

[4]  H. Chi,et al.  Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome , 2003, Leukemia.

[5]  G. Mufti,et al.  Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes , 2003, British journal of haematology.

[6]  N. Young,et al.  HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. , 2002, Blood.

[7]  N. Young,et al.  Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes , 2002, Annals of Internal Medicine.

[8]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[9]  M. Cazzola,et al.  Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. , 2002, Haematologica.

[10]  U. Germing,et al.  Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. , 2000, Leukemia research.

[11]  M. Tomonaga,et al.  New system for assessing the prognosis of refractory anemia patients , 1999, Leukemia.

[12]  T. Intragumtornchai,et al.  Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. , 1997, Leukemia research.

[13]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[14]  A. Ganser,et al.  Myelodysplastic syndromes: clinical features. , 1996, Seminars in hematology.

[15]  H. Koeffler,et al.  Differentiation therapy in myelodysplastic syndromes. , 1996, Seminars in hematology.

[16]  R. Larson,et al.  Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. , 1996, Leukemia.

[17]  H. Mizoguchi,et al.  Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare. , 1995, Leukemia research.

[18]  J. Mukiibi,et al.  Myelodysplastic syndromes (MDS) in Central Africans. , 1994, Tropical and geographical medicine.

[19]  A. Duhamel,et al.  Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. , 1993, Leukemia.

[20]  S. Asano,et al.  Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. , 1993, Leukemia.

[21]  A. Ganser,et al.  Clinical course of myelodysplastic syndromes. , 1992, Hematology/oncology clinics of North America.

[22]  Y. Rustum,et al.  Mechanisms of resistance to fluoropyrimidines. , 1992, Seminars in oncology.

[23]  Goasguen Je,et al.  Classification and morphologic features of the myelodysplastic syndromes. , 1992 .

[24]  U. Germing,et al.  Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.

[25]  J. Bennett,et al.  Classification and morphologic features of the myelodysplastic syndromes. , 1992, Seminars in oncology.

[26]  M. Sanz,et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.

[27]  D. Machin,et al.  Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.